YCT529

From Wikipedia the free encyclopedia

YCT529
Identifiers
  • 4-[5-[2,2-dimethyl-4-(4-methylphenyl)chromen-6-yl]-1H-pyrrol-2-yl]benzoic acid
PubChem CID
Chemical and physical data
FormulaC29H25NO3
Molar mass435.523 g·mol−1
3D model (JSmol)
  • CC1=CC=C(C=C1)C2=CC(OC3=C2C=C(C=C3)C4=CC=C(N4)C5=CC=C(C=C5)C(=O)O)(C)C
  • InChI=1S/C29H25NO3/c1-18-4-6-19(7-5-18)24-17-29(2,3)33-27-15-12-22(16-23(24)27)26-14-13-25(30-26)20-8-10-21(11-9-20)28(31)32/h4-17,30H,1-3H3,(H,31,32)
  • Key:QLXSCDXZOYRDAX-UHFFFAOYSA-N

YCT529 is a drug which acts as a potent and selective antagonist of the Vitamin A receptor retinoic acid receptor alpha (RAR-α). In studies on mice it produced a 99% reduction in sperm production, and it has proceeded to early stage human clinical trials as a potential male contraceptive.[1]

The Vitamin A signalling system plays a number of important roles in bodily systems, such as the Immune system “It seems to me inherently unlikely that a compound with such activity would be free of side effects,” says Richard Sharpe, of the University of Edinburgh.[2]

See also[edit]

References[edit]

  1. ^ "A non-hormonal pill could soon expand men's birth control options". ACS News. 23 March 2022.
  2. ^ Wilkins A (23 March 2022). "Male contraceptive pill is safe and effective in tests in mice". New Scientist.
Retrieved from "https://en.wikipedia.org/w/index.php?title=YCT529&oldid=1189902275"